<DOC>
	<DOCNO>NCT00074282</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pentostatin , cyclophosphamide , lenalidomide work different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : This phase II trial study well pentostatin , cyclophosphamide , rituximab , lenalidomide work treat patient relapsed refractory B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Pentostatin , Cyclophosphamide , Rituximab Followed By Lenalidomide Treating Patients With Relapsed Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate ( complete remission , partial remission [ PR ] , nodular PR ) patient relapsed refractory B-cell chronic lymphocytic leukemia ( CLL ) treat pentostatin , cyclophosphamide , rituximab ( PCR ) follow lenalidomide . - Determine presence minimal residual disease patient treat regimen . Secondary - Determine toxicity regimen patient . - Evaluate toxicity combine therapy , PCR lenalidomide , patient previously treat B-CLL . - Determine overall progression-free survival patient treat regimen . - Evaluate number patient PCR ( PCR PD ) , achieve PR , SD , PD subsequently convert high response category lenalidomide . - Correlate V_H gene mutation status CD38 expression CLL B-cell clone clinical outcome patient treat regimen . - Correlate differential expression gene leukemic cell clinical outcome patient treat regimen . - Correlate surface phenotype genetic defect CLL B-cell clone clinical outcome gene expression pattern patient treated regimen . Exploratory - Assess angiogenic profile ( i.e. , secretion level pro- versus anti-angiogenic molecule ) CLL B cell clone well bone marrow angiogenesis ( i.e. , vascular density immunohistochemistry ) baseline , PCR , lenalidomide , every six month ( serum ) , time response assessment ( marrow ) . - Determine V_H gene mutation status CD38 expression B-CLL clone study entry end therapy ass association VH gene mutation status CD38 expression clinical outcome . - Determine surface phenotype ( flow cytometry ) genetic defect ( CLL FISH panel ) information CLL-B cell clone associate clinical outcome . - Monitor T-cell status repertoire flow cytometry analysis determine nature extent T-cell deficiency induce PCR lenalidomide treatment ass association clinical outcome toxicity . OUTLINE : This multicenter study . Pentostatin , cyclophosphamide , rituximab ( PCR ) * therapy : Patients receive pentostatin IV 10-30 minute , cyclophosphamide IV 30-60 minute , rituximab** IV day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 3 pegfilgrastim SC day 1 continue blood count recover . Treatment repeat every 28 day total 6 course absence unacceptable toxicity . NOTE : *Patients demonstrate progression receive PCR must complete 2 course PCR prior proceed lenalidomide therapy . NOTE : **Patients receive rituximab IV day 1 , 3 , 5 course 1 ; course 2-6 , patient receive rituximab day 1 . Lenalidomide*** therapy : Eight week completion PCR therapy diagnose progressive disease , patient receive lenalidomide orally ( PO ) day 1-28 . In absence disease progression unacceptable toxicity , treatment repeat every 28 day patient partial remission ( PR ) , stable disease , progressive disease PCR . Patients achieve complete remission proceed clinical observation . NOTE : ***The alemtuzumab therapy replace lenalidomide therapy May , 2011 . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 26-110 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) meeting follow criterion : Peripheral blood absolute lymphocyte count great 5,000/mm^3 Lymphocytosis must comprise small moderate size lymphocyte great 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Phenotypically characterize CLL define follow : Predominant population cell share Bcell antigens CD5 absence panTcell marker ( CD3 CD2 ) B cell express either kappa lambda light chain Surface immunoglobulin low cell surface density expression Requires chemotherapy , indicate following : Diseaserelated symptom Weight loss 10 % within past 6 month Extreme fatigue Fevers great 100.5°F 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure manifest development worsen anemia ( hemoglobin great 10 g/dL ) and/or thrombocytopenia ( platelet count great 100,000/mm^3 ) Massive ( i.e. , great 6 cm leave costal margin ) progressive splenomegaly Massive nod cluster ( i.e. , great 10 cm long diameter ) progressive adenopathy Progressive lymphocytosis increase great 50 % 2month period OR anticipate double time le 6 month Demonstrated progression least 1 course either alkylating agentbased purine nucleosidebased ( e.g. , fludarabine ) regimen OR fail achieve meaningful response OR relapse prior therapy Patients relapse pentostatinbased regimen eligible provide response great 12 month prior study entry No bone marrow dysplasia relate prior therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin great 2 mg/dL ( unless secondary tumor , hemolysis , Gilbert syndrome ) Renal Creatinine great 2.0 mg/dL OR Creatinine clearance ≥ 30 mL/min Cardiovascular No New York Heart Association class III IV heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception ( include 1 barrier method ) least 28 day start lenalidomide , participate study , least 28 day discontinuation/stopping lenalidomide No malignancy within past 2 year except squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy At least 8 week since prior rituximab Chemotherapy See Disease Characteristics At least 6 week since prior chemotherapy At least 1 year since prior pentostatin , cyclophosphamide , rituximab ( PCR ) therapy PCR therapy least 1 year prior study entry allow No prior lenalidomide Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent oral IV antibiotic active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>